Neurocrine Biosciences NBIX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's operating cash flow?
- Neurocrine Biosciences (NBIX) reported operating cash flow of $145.8M in Q1 2026.
- How has Neurocrine Biosciences's operating cash flow changed year-over-year?
- Neurocrine Biosciences's operating cash flow increased by 125.0% year-over-year, from $64.8M to $145.8M.
- What is the long-term trend for Neurocrine Biosciences's operating cash flow?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's operating cash flow has grown at a 32.2% compound annual growth rate (CAGR), from $256.5M to $782.7M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.